Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,901–6,000 of 15,747
Abou-Saleh, H., Halawa, B. Y. A., Younes, S. N., Younes, N., Al‐Sadeq, D. W., Shurrab, F. M., Liu, N., Qotba, H. A., Al-Dewik, N. I. E., Ismail, A., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac130 · Cited by 18
“In addition, equally remarkable clinical trial data showed rapid induction of mRNA protective efficacy on a timescale similar to our current study.(3,5) However, despite the mRNA vaccination-boosted antibody levels, this ‘boost’ was relatively short-lived, with ∼ 2- to 6fold significant waning observed in NTAb, anti-S…”
MethodResult(2021) · doi:10.1101/2021.01.05.21249247 · Cited by 86
Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers
Mitsikostas, D. D., Aravantinou-Fatorou, K., Deligianni, C. I., Kravvariti, E., Korompoki, E., Mylona, M., Vryttia, P., Papagiannopoulou, G., Delicha, E.-M., Dellis, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9101179 · Cited by 14
“As in our study, only a few recipients used medical treatments for these AEs, and systemic AEs were more prevalent after the second dose [30].”
ResultNon-Canonical Host Intracellular Niche Links to New Antimicrobial Resistance Mechanism
Kember, M., Grandy, S. L., Raudonis, R., & Cheng, Z. (2022) · Pathogens · doi:10.3390/pathogens11020220 · Cited by 18
Kasting, M. L., Macy, J. T., Grannis, S. J., Wiensch, A., Ferres, J. L., & Dixon, B. E. (2022) · JMIR Public Health and Surveillance · doi:10.2196/37203 · Cited by 18
Involvement of the STING signaling in COVID-19
Xiao, R., & Zhang, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006395 · Cited by 15
“Moreover, a number of vaccines has been developed to prevent the infection of SARSCoV-2, such as BNT162b2 and mRNA-1273, demonstrating appreciable efficacy in phase III clinical trials (12, 13).”
BackgroundGoncheva, M. I., Gibson, R. M., Shouldice, A. C., Dikeakos, J. D., & Heinrichs, D. E. (2023) · iScience · doi:10.1016/j.isci.2023.105975 · Cited by 16
Oduwole, E. O., Esterhuizen, T. M., Mahomed, H., & Wiysonge, C. S. (2021) · Vaccines · doi:10.3390/vaccines9111246 · Cited by 16
Hedges, J. F., Thompson, M. A., Snyder, D. T., Robison, A., Taylor, M. P., & Jutila, M. A. (2021) · Vaccines · doi:10.3390/vaccines9060587 · Cited by 14
“Protectio from infection has been asse sed for pa ticipants in vaccine clinical trials [5,6] and the comparison of antibody titers and neutralization ca ci y induced by the vaccines comp red to those g nerated in response to natural infection is of interest.”
BackgroundMotta, F. C., McGoff, K. A., Deckard, A., Wolfe, C. R., Bonsignori, M., Moody, M. A., Cavanaugh, K., Denny, T. N., Harer, J., & Haase, S. B. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.3035 · Cited by 16
Violán, C., Carrasco-Ribelles, L., Collatuzzo, G., Ditano, G., Abedini, M., Janke, C., Reinkemeyer, C., Giang, L. T. T., Liviero, F., Scapellato, M. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11081340 · Cited by 14
Sherman, A. C., Gray, G., Cao, B., To, K. K., Rouphael, N., Restrepo, A. M. H., Gordon, A. C., & Baden, L. R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00662-x · Cited by 23
“Although the currently approved COVID-19 vaccines had remarkable efficacy in the phase III licensure trials 128,130,131 , there is a need to develop improved vaccines that have enhanced breadth across emerging variants, are durable, and reduce or block transmission.”
COVID-19 vaccine hesitancy in care home staff: A survey of Liverpool care homes
Tulloch, J. S. P., Lawrenson, K., Gordon, A. L., Ghebrehewet, S., Ashton, M., Peddie, S., & Parvulescu, P. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.009 · Cited by 15
Borroni, E., Consonni, D., Cugno, M., Lombardi, A., Mangioni, D., Bono, P., Oggioni, M., Renteria, S. U., Bordini, L., Nava, C. D., et al. (2021) · La Medicina del Lavoro · doi:10.23749/mdl.v112i6.12507 · Cited by 19
“However, either the BNT162b2 RCT (10) or other studies among HCWs reported no serious AEs after the first dose (19, 22, 23).”
BackgroundResultInfluentialSARS‐CoV‐2 infection after two doses of mRNA vaccine in renal transplant recipients
Bašić‐Jukić, N., & Jelicić, I. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13628 · Cited by 14
Ukey, R., Bruiners, N., Mishra, H. K., Mishra, P. K., McCloskey, D., Onyuka, A., Chen, F., Pinter, A., Weiskopf, D., Sette, A., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02252-0 · Cited by 17
“The SARS-CoV-2 vaccines that have received full approval or emergency use authorization by the US Food and Drug administration include the mRNA vaccines BNT162b2 (BioNTech-Pfizer) [2] and mRNA-1273 (Moderna) [3], which are administered in two doses, and the single-dose, adenoviral vector vaccine Ad26.”
Reimann, H., Kremer, A. N., Blumenberg, V., Schmidt, K. G., Aigner, M., Jacobs, B., Eisenhauer, N., Kämpf, A., Rösler, W., Kharboutli, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007806 · Cited by 18
“Immense efforts led to a rapid development of vaccines protecting from SARS‐CoV‐2 infections.(2,3)”
ALC-0315 Lipid-Based mRNA LNP Induces Stronger Cellular Immune Responses Postvaccination
Song, Z., Jin, L., Jiao, L., Yu, R., Liu, H., Zhang, S., Hu, Y., Sun, Y., Li, E., Zhao, G., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00995 · Cited by 17
Peter, J. K., Wegner, F., Gsponer, S., Helfenstein, F., Roloff, T. C., Tarnutzer, R., Grosheintz, K., Back, M., Schaubhut, C., Wagner, S., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10050857 · Cited by 13
Greenberg, R. S., Ruddy, J. A., Boyarsky, B. J., Werbel, W. A., Garonzik‐Wang, J., Segev, D. L., & Imus, P. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-09097-5 · Cited by 14
“While high immunogenicity in MM patients is promising, clinical trials in the general population reported a 100% seroconversion rate for both vaccine types [3, 4].”
BackgroundResultLipid Nanoparticles Outperform Electroporation in Delivering Therapeutic HPV DNA Vaccines
Li, M., Liu, L., Li, X., Li, J., Zhao, C., Zhao, Y., Zhang, X., He, P., Wu, X., Jiang, S., et al. (2024) · Vaccines · doi:10.3390/vaccines12060666 · Cited by 14
“Patisiran is used to treat hereditary transthyretin-mediated (hATTR) amyloidosis, BNT162b2 and mRNA-1273 are both SARS-COVID-19 vaccines, and mRESVIA (mRNA-1345) is the respiratory syncytial virus (RSV) vaccine for older adults [16–19].”
BackgroundKeep, S., Stevenson-Leggett, P., Dowgier, G., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01100-22 · Cited by 14
The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control
MacIntyre, C. R., Costantino, V., & Chanmugam, A. S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.102 · Cited by 15
“We modelled the use of a high efficacy vaccine such as Pfizer or Moderna, which are being used in the US [21,22].”
MethodCalcaterra, V., Zanelli, S., Foppiani, A., Verduci, E., Benatti, B., Bollina, R., Bombaci, F., Brucato, A. L., Cammarata, S., Calabrò, E., et al. (2024) · Diseases · doi:10.3390/diseases12050095 · Cited by 20
Kong, L., Wang, X., Chen, H., Shi, Z., Lang, Y., Zhang, Y., & Zhou, H. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104167 · Cited by 15
Modern vaccine development via reverse vaccinology to combat antimicrobial resistance
Tobuse, A. J., Wei, A. C., & Yeong, K. Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120660 · Cited by 18
Hamaya, T., Hatakeyama, S., Yoneyama, T., Tobisawa, Y., Kodama, H., Fujita, T., Murakami, R., Fujita, N., Okamoto, T., Yamamoto, H., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09897-0 · Cited by 13
mRNA vaccines as cancer therapies
Huang, S., Que, H., Wang, M., & Wei, X. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003455 · Cited by 19
SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usagePreprint
Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434497 · Cited by 14
McCollum, C. R., Courtney, C. M., O’Connor, N. J., Aunins, T. R., Jordan, T. X., Rogers, K. L., Brindley, S. M., Brown, J. M., Nagpal, P., & Chatterjee, A. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00669 · Cited by 12
Cao, K. T., Cobos-Uribe, C., Knight, N., Jonnalagadda, R., Robinette, C., Jaspers, I., & Rebuli, M. (2023) · Journal of Allergy and Clinical Immunology: Global · doi:10.1016/j.jacig.2023.100129 · Cited by 15
“As the SARS-CoV-2 mRNA vaccines encode for the systemic production of antibodies targeting epitopes of the SARS-CoV-2 Spike protein, most notably the receptor binding domain (RBD), but also the N-terminal domain (NTD) and S2, these epitopes were primary targets of analysis with S2 binding measured indirectly(10).”
BackgroundCOVID-19 and severity of liver diseases: Possible crosstalk and clinical implications
Imam, M. T., Almalki, Z. S., Alzahrani, A. R., Al-Ghamdi, S. S., Falemban, A. H., Alanazi, I. M., Shahzad, N., Alrooqi, M. M., Jabeen, Q., & Shahid, I. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110439 · Cited by 15
Barge, S., Jade, D., Gosavi, G., Talukdar, N. C., & Borah, J. C. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105820 · Cited by 12
Glikman, D., Stein, M., & Shinwell, E. S. (2021) · Acta Paediatrica · doi:10.1111/apa.15982 · Cited by 13
Casado, J. L., Häemmerle, J., Vizcarra, P., Rodríguez-Domínguez, M., Velasco, T., Velasco, H., Centenera, E., Romero‐Hernández, B., Fernández-Escribano, M., & Vallejo, A. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1341 · Cited by 13
Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19
Yegiazaryan, A., Abnousian, A., Alexander, L. J., Badaoui, A., Flaig, B., Sheren, N., Aghazarian, A., Alsaigh, D., Amin, A., Mundra, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169297 · Cited by 14
“Both mRNA vaccines elicit a Th1 immune response, with levels of antigen specific CD8+ memory cells and CD4+ T-cells greatly increased [112].”
BackgroundSARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity
Tobias, J., Steinberger, P., Wilkinson, J., Klais, G., Kundi, M., & Wiedermann, U. (2024) · Vaccines · doi:10.3390/vaccines12070795 · Cited by 17
Guerstein, S., Romeo-Aznar, V., Dekel, M., Miron, O., Davidovitch, N., Puzis, R., & Pilosof, S. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009319 · Cited by 22
“where e is vaccine efficiency, set to 95% [37].”
COVID-19 vaccines: A perspective from social pharmacology
Montastruc, J., Lafaurie, M., de Canecaude, C., Montastruc, F., Bagheri, H., Durrieu, G., & Sommet, A. (2021) · Therapies · doi:10.1016/j.therap.2021.05.010 · Cited by 15
Gregersen, C. H., Mearraoui, R., Søgaard, P. P., Clergeaud, G., Petersson, K., Urquhart, A. J., & Simonsen, J. B. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114219 · Cited by 14
Arwansyah, A., Arif, A. R., Ramli, I., Kurniawan, I., Sukarti, S., Alam, M., Illing, I., Lewa, A. F., & Manguntungi, B. (2021) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2021.1960601 · Cited by 14
Abdel‐Bakky, M. S., Amin, E., Ewees, M. G., Mahmoud, N. I., Mohammed, H. A., Altowayan, W. M., & Abdellatif, A. A. H. (2022) · Viruses · doi:10.3390/v14020228 · Cited by 17
Prioritization preferences for COVID-19 vaccination are consistent across five countries
Munzert, S., Ramirez-Ruiz, S., Çalı, B., Stoetzer, L. F., Gohdes, A., & Lowe, W. (2022) · Humanities and Social Sciences Communications · doi:10.1057/s41599-022-01392-1 · Cited by 15
Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V., Victor, E. D. S., Pinho, J. R. R., Cypriano, A. S., Vieira, L. W., Polonio, M., et al. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.50 · Cited by 14
“5 Our study showed that the estimated vaccine effectiveness rates after 2 doses of CoronaVac and ChAdOx1 among HCWs were lower than the vaccine effectiveness rates of mRNA COVID-19 vaccines among the general population reported in the randomized trials 11,12 and also in a noncontrolled setting.”
Vaccines for Covid‐19: An insight on their effectiveness and adverse effects
Qamar, N., Rukh, G., & Khan, S. N. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27810 · Cited by 13
“The Pfizer–BioNTech BNT162b2 is a messenger RNA vaccine that shows 95% efficacy against SARS‐COVID‐19.19,51 The Pfizer‐vaccine is composed of ALC‐0315, potassium chloride, cholesterol, sodium chloride, disodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate sucrose, and water for injection.52 The effecti…”
BackgroundInfluentialA Vaccination Simulator for COVID-19: Effective and Sterilizing Immunization Cases
Karabay, A., Kuzdeuov, A., Ospanova, S., Lewis, M., & Varol, H. A. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3114180 · Cited by 14
Leomanni, L., Collatuzzo, G., Sansone, E., Sala, E., Palma, G. D., Porru, S., Spiteri, G., Monaco, M. G. L., Basso, D., Pavanello, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11101527 · Cited by 17
Immunologic response to SARS-CoV-2 mRNA vaccination in pediatric kidney transplant recipients
Kermond, R., Ozimek-Kulik, J. E., Kim, S., Alexander, S. I., Hahn, D., Kesson, A. M., Wood, N., McCarthy, H. J., & Durkan, A. M. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05679-y · Cited by 14
“SARS-CoV-2 vaccines have been shown to be safe and efficacious in lowering the rates of SARS-CoV-2 infection, intensive care unit (ICU) admissions, and death in previously healthy adults [11, 12].”
BackgroundA puzzle of proportions: Two popular Bayesian tests can yield dramatically different conclusions
Dablander, F., Huth, K. B. S., Gronau, Q. F., Etz, A. J., & Wagenmakers, E. (2021) · Statistics in Medicine · doi:10.1002/sim.9278 · Cited by 15
“F I G U R E 4 Top: Bayes factors using the IB (rectangles) and LT approach (circles) in favor of 0 across studies reported in Hoekstra et al17 (left) or for simulated equal proportions with n = 100 (right) for values a ∈ [1, 5] and σψ ∈ [1, 2] with σβ = 1.”
Callaghan, C. J., Curtis, R. M. K., Mumford, L. L., Whitaker, H., Pettigrew, G. J., Gardiner, D. D., Marson, L., Thorburn, D., White, S. A., Parmar, J., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004535 · Cited by 15
Almeida, N. D., Schiller, I., Ke, D., Sakr, E., Plesa, M., Vanamala, S., Moneger, A.-L., Bazan, M., Lucchesi, C., Woźniak, N. J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330549 · Cited by 16
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Bohehm, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R. (2021) · medRxiv · doi:10.1101/2021.02.22.21252002 · Cited by 17
Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities
Liu, S., Kang, M., Zhao, N., Zhuang, Y., Li, S., & Song, T. (2022) · Medical Review · doi:10.1515/mr-2021-0021 · Cited by 15
Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase
Prugger, C., Spelsberg, A., Keil, U., Erviti, J., & Doshi, P. (2021) · BMJ · doi:10.1136/bmj-2021-067570 · Cited by 17
Divalent Metal Ions Boost Effect of Nucleic Acids Delivered by Cell-Penetrating Peptides
Maloverjan, M., Padari, K., Abroi, A., Rebane, A., & Pooga, M. (2022) · Cells · doi:10.3390/cells11040756 · Cited by 13
“mRNA-1273 (Moderna) [3] and BNT162b2 (Pfizer-BioNTech) [4], became major tools and preferred method of fighting COVID-19 pandemic overworld.”
MethodEarly Mortality After the First Dose of COVID-19 Vaccination: A Target Trial Emulation
McConeghy, K. W., Hur, K., Dahabreh, I. J., Jiang, R., Pandey, L., Gellad, W. F., Glassman, P. A., Good, C. B., Miller, D. R., Zullo, A. R., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad604 · Cited by 15
Li, L., Zheng, C., La, J., Do, N., Monach, P. A., Strymish, J. M., Fillmore, N. R., & Branch‐Elliman, W. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.026 · Cited by 15
Immunization-Associated Corneal Transplantation Rejection: A Review
Lee, E. H., & Li, J. Y. (2021) · Cornea · doi:10.1097/ico.0000000000002898 · Cited by 14
The global patent landscape of mRNA for diagnosis and therapy
Lyu, M., Chen, J., Peng, Y., Han, F., Gong, L., Guo, J., Tian, L., & Gao, Y. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01925-2 · Cited by 16
Broudic, K., Laurent, S., Perkov, V., Simon, C., Garinot, M., Truchot, N., Latour, J., & Désert, P. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4548 · Cited by 16
“Moreover, a third dose of MRT5500 administered as a booster to the currently approved two doses regimens (Jackson et al., 2020; Polack et al., 2020) has shown to effectively promote broadly neutralizing antibodies against all variants of concerns in NHPs (Kalnin et al., 2022).”
BackgroundCOVID-19 Vaccination Among the Arab Bedouin Population: Lessons Learned From a Minority Population
Abu‐Freha, N., Alsana, H., El‐Saied, S., et al. (2022) · International Journal of Public Health · doi:10.3389/ijph.2022.1604133 · Cited by 14
Kaneko, H., & Tsuboi, H. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.09.004 · Cited by 14
Ginger supplement significantly reduced length of hospital stay in individuals with COVID-19
Li, Y., Yang, D., Gao, X., Ju, M., Fang, H., Yan, Z., Qu, H., Zhang, Y., Xie, L., 翁惠芬, et al. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00717-w · Cited by 16
“While immunization with vaccines proved the efficacy of protecting people from virus infection [1, 2], with the emerging new strains of the virus and decay of antibodies after vaccination [3, 4], the risk of infection could increase [5].”
BackgroundPrasad, N. K., Englum, B. R., Mayorga‐Carlin, M., Turner, D. J., Sahoo, S., Sorkin, J. D., & Lal, B. K. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.03.038 · Cited by 14
Safe Surgery During the COVID-19 Pandemic
Singhal, R., Dickerson, L., Sakran, N., Pouwels, S., Chiappetta, S., Weiner, S. R., Purkayastha, S., Madhok, B., & Mahawar, K. K. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00458-6 · Cited by 18
Electromechanical convective drug delivery devices for overcoming diffusion barriers
Park, J., Ghanim, R. W., Rahematpura, A., Gerage, C., & Abramson, A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.008 · Cited by 16
Thompson, K. M., Kalkowska, D. A., & Badizadegan, K. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1891889 · Cited by 14
Warpechowski, J. J., Leszczyńska, P., Juchnicka, D., Olichwier, A. J., Szczerbiński, Ł., & Kretowski, A. J. (2023) · Vaccines · doi:10.3390/vaccines11071203 · Cited by 21
Murphy, E. A., Guzmán-Cardozo, C., Sukhu, A. C., Park, D., Prabhu, M., Mohammed, I. A., Jurkiewicz, M., Ketas, T. J., Singh, S., Canis, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39989-y · Cited by 17
Telemedicine use in orthopaedics: Experience during the COVID-19 pandemic
Chin, B. Z., Nashi, N., Lin, S., Yik, K., Tan, G. Y. H., & Kagda, F. H. Y. (2021) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x211041011 · Cited by 16
Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies
Huang, X., Liang, X., Zhang, J., Su, H., & Chen, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11143968 · Cited by 15
“[26] have demonstrated 95% protective efficacy of the two-dose regimen of BNT162b2 conferred in patients aged > 16 years, with remarkable safety and mostly mild-to-moderate adverse events.”
BackgroundWang, G., & Kwok, S. W. H. (2021) · IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI ...) · doi:10.1109/bhi50953.2021.9508578 · Cited by 14
Using negative controls to adjust for unmeasured confounding bias in time series studies
Hu, J. K., Tchetgen, E. J. T., & Dominici, F. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00249-4 · Cited by 20
“(1) and (2), and β β , a u and ηwu are regression coefficients.”
BackgroundInfluentialAbe, S., Takata, H., Shimizu, T., Kawaguchi, Y., Fukuda, S., Yamamoto, H., Ando, H., & Ishida, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113821 · Cited by 22
Aabakken, L., Ebigbo, A., Antonelli, G., et al. (2021) · Endoscopy International Open · doi:10.1055/a-1400-9135 · Cited by 14
Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
McMillan, C. L. D., Choo, J. J., Idris, A., Supramaniam, A., Modhiran, N., Amarilla, A., Isaacs, A., Cheung, S. T. M., Liang, B., Bielefeldt-Ohmann, H., et al. (2021) · bioRxiv · doi:10.1101/2021.05.30.446357 · Cited by 45
“a single dose to achieve protection would mean fewer doses to be manufactured and more rapid vaccine coverage of populations, in contrast to most current SARS-CoV-2 vaccines which require 2 doses 3-12 weeks apart to achieve protection (59-62).”
Jahangir, M. A. (2021) · International Journal of Pharmaceutics & Pharmacology · doi:10.31531/2581-3080.1000153 · Cited by 13
“The Covaxin is reported to effectively neutralize the U.K variant B.1.17 and Indian Variant B.1.617 of SARS-COVID-2.”
InfluentialMa, Z., Tong, H., Lin, S., Li, Z., Sun, D., Li, B., Tian, C., & Chu, J. (2023) · Nano Research · doi:10.1007/s12274-023-6031-1 · Cited by 15
Covid19 Vaccines and the Misinterpretation of Perceived Side Effects
Palmer, R. F. (2022) · Biomedicine · doi:10.37796/2211-8039.1371 · Cited by 15
Oh, T.-H., Woo, S. H., Hong, S., Lee, C., Lee, W. J., & Jeong, S. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e73 · Cited by 15
Lü, Y. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003697 · Cited by 14
Levi, N., Moravsky, G., Weitsman, T., Amsalem, I., Itach, S. B., Algur, N., Lapidus, I., Mitz, O., Glikson, M., Weil‐Weiner, Y., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2687 · Cited by 15
Hing, N. Y. L., Woon, Y. L., Lee, Y. K., Kim, H. J., Lothfi, N. M., Wong, E. R., Perialathan, K., Sanusi, N. H. A., Isa, A., Leong, C. T., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-009250 · Cited by 19
Wang, Y., Wei, X., Liu, Y., Li, S., Pan, W., Dai, J., & Yang, Z. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1412478 · Cited by 22
COVID Vaccination as a Strategy for Cardiovascular Disease Prevention
Fundora, M. P., Kamidani, S., & Oster, M. E. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01950-2 · Cited by 16
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 23
mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Dalabehera, M., Ghosh, A., Mohanty, S., Chellappan, D. K., Chaudhari, S., Ale, Y., Poonia, N., Subudhi, R. N., Khanna, M., & Lim, H. G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102584 · Cited by 27
“A key development (Karik ´ o & Weissman, 2023 Nobel Prize) came in 2005 [3], when it was shown that certain modified nucleosides could be incorporated into mRNA to suppress activation of Toll-like receptors (TLR) and other sensors.”
Niebel, D., Wilhelmi, J., de Vos, L., et al. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.16210 · Cited by 14
Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients
Hirama, T., Akiba, M., Shundo, Y., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.04.019 · Cited by 14
“Based on the current evidence [12,13], a two-dose mRNA vaccine regimen is effective to minimize COVID-19 in the non-transplanted population and can lead to a humoral immune response with high IgG titers that is similar to those of individuals who were infected with SARS-CoV-2 [14,15].”
Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting
Garces, K. N., Cocores, A. N., Goadsby, P. J., & Monteith, T. (2022) · Current Pain and Headache Reports · doi:10.1007/s11916-022-01094-y · Cited by 14
“In the BNT162b2 mRNA COVID19 vaccine trial, younger recipients were more likely to report taking an antipyretic or pain medication in response to a moderate or severe headache than older recipients [56].”
BackgroundInfluentialCouture‐Senécal, J., Tilstra, G., & Khan, O. F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.02.606386 · Cited by 17
Itamochi, M., Yazawa, S., Inasaki, N., Saga, Y., Yamazaki, E., Shimada, T., Tamura, K., Maenishi, E., Isobe, J., Nakamura, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.068 · Cited by 15
“In randomized, controlled trials conducted in 2020, the COVID-19 messenger RNA (mRNA) vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), were more than 90 % effective at preventing COVID19 approximately 2 months after vaccination [6,7].”
Current development of Zika virus vaccines with special emphasis on virus-like particle technology
Cimica, V., Galarza, J. M., Rashid, S., & Stedman, T. T. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1945447 · Cited by 13
Cost-effectiveness analysis of COVID-19 vaccination in Poland
Orlewska, K., Wierzba, W., & Śliwczyński, A. M. (2021) · Archives of Medical Science · doi:10.5114/aoms/144626 · Cited by 16
“Single-dose efficacy was 52 %, twodose efficacy was 95% [4].”
BackgroundInfluentialEstimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology
McMenamin, M. E., Bond, H. S., Sullivan, S. G., & Cowling, B. J. (2022) · Epidemiology · doi:10.1097/ede.0000000000001473 · Cited by 18
Zabaleta, N., Bhatt, U., Hérate, C., Maisonnasse, P., Sanmiguel, J. C., Diop, C. T., Castore, S., Estelien, R., Li, D., Dereuddre‐Bosquet, N., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.007 · Cited by 17
Simão, A. L., Palma, C. S., Izquierdo‐Sánchez, L., Putignano, A., Carvalho‐Gomes, Â., Posch, A., Zanaga, P., Gîrleanu, I., Henrique, M. M., Araújo, C., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100697 · Cited by 14
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.